Literature DB >> 1774449

Immunodetection of thyroid tumors: role of immuno aggregates.

A J Van Herle1, B Estour, G Juillard, A Giuliano, R A Hawkins, K Van Herle.   

Abstract

To understand the inconsistent immunodetection of tumors in vivo, a labelled monoclonal antibody (MAb) against a human follicular cancer cell line (UCLA RO 82 W-1) was used as a model for in vitro and in vivo studies. The 131I labelled MAb x RO 82 W-1 bound to its target cells (10% to 70%) mainly because of the generation of immunoglobulin aggregates. Aggregates generated by the freezing process were shown by polyacrylamide gel electrophoresis (PAGE) and their removal by filtration. When the aggregated 131I MAb x RO 82 W-1 was injected into BALB/c mice bearing UCLA RO 82 W-1 tumors, a high tumor/blood ratio was found in the large tumors. The tracer concentrated in the macroscopically visible necrotic part of the tumor was largely responsible for the scintigraphic detection. Irrelevant 131I-IgG also concentrated in necrotic regions of tumors. Scintigraphic detection of thyroid tumors in this model was related to the degree to which labeled aggregates of IgG, regardless of their specificity, localized in necrotic regions of the tumors.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1774449     DOI: 10.1007/BF03347885

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  22 in total

1.  Indirect 125I-labeled protein A assay for monoclonal antibodies to cell surface antigens.

Authors:  J P Brown; J D Tamerius; I Hellström
Journal:  J Immunol Methods       Date:  1979       Impact factor: 2.303

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  Imaging of human tumor xenografts in nude mice with radiolabeled monoclonal antibodies. Limitations of specificity due to nonspecific uptake of antibody.

Authors:  B D Mann; M B Cohen; R E Saxton; D L Morton; W F Benedict; E L Korn; L Spolter; L S Graham; C C Chang; M W Burk
Journal:  Cancer       Date:  1984-10-01       Impact factor: 6.860

4.  Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning.

Authors:  D M Goldenberg; F DeLand; E Kim; S Bennett; F J Primus; J R van Nagell; N Estes; P DeSimone; P Rayburn
Journal:  N Engl J Med       Date:  1978-06-22       Impact factor: 91.245

5.  Radioimmunodetection of human colon carcinoma xenografts in visceral organs of congenitally athymic mice.

Authors:  J Lundy; F Mornex; A M Keenan; J W Greiner; D Colcher
Journal:  Cancer       Date:  1986-02-01       Impact factor: 6.860

6.  In vivo imaging of intracranial human glioma xenografts comparing specific with nonspecific radiolabeled monoclonal antibodies.

Authors:  D E Bullard; C J Adams; R E Coleman; D D Bigner
Journal:  J Neurosurg       Date:  1986-02       Impact factor: 5.115

7.  Uptake and localization of 131I-labeled anti-calcitonin immunoglobulins in rat medullary thyroid carcinoma tissue.

Authors:  K M Gautvik; K Svindahl; A Skretting; B Stenberg; L Myhre; A Ekeland; J V Johannesen
Journal:  Cancer       Date:  1982-09-15       Impact factor: 6.860

8.  111In-labeled nonspecific immunoglobulin scanning in the detection of focal infection.

Authors:  R H Rubin; A J Fischman; R J Callahan; B A Khaw; F Keech; M Ahmad; R Wilkinson; H W Strauss
Journal:  N Engl J Med       Date:  1989-10-05       Impact factor: 91.245

9.  Receptors for aggregated IgG on mouse lymphocytes: their presence on thymocytes, thymus-derived, and bone marrow-derived lymphocytes.

Authors:  C L Anderson; H M Grey
Journal:  J Exp Med       Date:  1974-05-01       Impact factor: 14.307

10.  Localization of human tumour xenografts after i.v. administration of radiolabeled monoclonal antibodies.

Authors:  V Moshakis; R A McIlhinney; D Raghavan; A M Neville
Journal:  Br J Cancer       Date:  1981-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.